Oxi 4503 clinical trials
Also written OXi4503.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses Oxi 4503 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Mateon Therapeutics (3) · University of Florida (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses Oxi 4503 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSStatus unknownPhase 1/2Mateon TherapeuticsNCT02576301Written as Phase 1 - OXi4503How we know
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSTerminatedPhase 1University of FloridaNCT01085656Written as OXi4503How we know
- Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid TumorsCompletedPhase 1Mateon TherapeuticsNCT00977210Written as OXi4503How we know
- Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor BurdenCompletedPhase 1Mateon TherapeuticsNCT00960557Written as Combretastatin A1 Diphosphate (OXi4503)How we know
Codes
What other systems call Oxi 4503 · ClinicalTrials.gg INT004475
- UNII (FDA) JH6Z94GLUDCOMBRETASTATIN A-1 PHOSPHATEConfirmed FDA, Wikidata
- Wikidata Q27095572OXI-4503Confirmed FDA, Wikidata
- DrugBank DB05143One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JH6Z94GLUD | COMBRETASTATIN A-1 PHOSPHATE | Confirmed FDA, Wikidata |
| Wikidata | Q27095572 | OXI-4503 | Confirmed FDA, Wikidata |
| DrugBank | DB05143 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.